

Alain Bergeron

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3772085/alain-bergeron-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31
papers

2,850
citations

15
h-index

32
g-index

32
ext. papers

3,614
ext. citations

11.6
avg, IF

3.44
L-index

#	Paper	IF	Citations
31	Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype.. <i>Clinical and Translational Medicine</i> , 2022 , 12, e581	5.7	4
30	Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity. <i>Molecular Cancer Research</i> , 2021 , 19, 516-527	6.6	3
29	Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival. <i>World Journal of Urology</i> , 2021 , 39, 1549-1558	4	3
28	Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression. <i>OncImmunity</i> , 2020 , 9, 1851950	7.2	2
27	Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer. <i>Frontiers in Genetics</i> , 2020 , 11, 550894	4.5	3
26	Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. <i>PLoS Medicine</i> , 2020 , 17, e1003281	11.6	8
25	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. <i>Nature Medicine</i> , 2019 , 25, 1615-1626	50.5	25
24	Large-Scale Automatic Feature Selection for Biomarker Discovery in High-Dimensional OMICs Data. <i>Frontiers in Genetics</i> , 2019 , 10, 452	4.5	27
23	Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate. <i>Radiation Oncology</i> , 2019 , 14, 60	4.2	11
22	Widespread and Functional RNA Circularization in Localized Prostate Cancer. <i>Cell</i> , 2019 , 176, 831-843.e236	26.2	214
21	Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice. <i>Prostate</i> , 2019 , 79, 9-20	4.2	16
20	Validation of the prognostic value of NF- κ B p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. <i>PLoS Medicine</i> , 2019 , 16, e1002847	11.6	15
19	The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival. <i>Prostate</i> , 2018 , 78, 697-706	4.2	13
18	Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5 α -reductase inhibitors. <i>BJU International</i> , 2018 , 121, 399-404	5.6	8
17	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. <i>BMC Urology</i> , 2018 , 18, 78	2.2	6
16	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , 2017 , 541, 359-364	50.4	320
15	A Prostate Cancer "Nimbofus": Genomic Instability and SchLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017 , 72, 665-674	10.2	98

14	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , 2017 , 72, 22-31	10.2	28
13	Poly(I:C) potentiates Bacillus Calmette-Guërin immunotherapy for bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 223-34	7.4	15
12	Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction. <i>Cancer Prevention Research</i> , 2016 , 9, 189-95	3.2	7
11	Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer. <i>Cancer Immunology Research</i> , 2016 , 4, 881-892	12.5	36
10	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , 2015 , 163, 1011-25	56.2	1713
9	IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness. <i>Research and Reports in Urology</i> , 2014 , 6, 27-34	1.3	23
8	Cystatin C for early detection of acute kidney injury after laparoscopic partial nephrectomy. <i>Urology Annals</i> , 2014 , 6, 298-304	1	3
7	Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guërin immunotherapy. <i>European Urology</i> , 2009 , 55, 1386-95	10.2	85
6	High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. <i>International Journal of Cancer</i> , 2009 , 125, 1365-71	7.5	70
5	MAGE-A9 mRNA and protein expression in bladder cancer. <i>International Journal of Cancer</i> , 2007 , 120, 2170-7	7.5	31
4	Cancer-testis antigen expression in bladder cancer. <i>Progres En Urologie</i> , 2006 , 16, 421-8	0.9	14
3	Influence of spatial configuration on the expression of carcinoembryonic antigen and mucin antigens in human bladder cancer. <i>International Journal of Cancer</i> , 1997 , 71, 986-92	7.5	8
2	MAUB is a new mucin antigen associated with bladder cancer. <i>Journal of Biological Chemistry</i> , 1996 , 271, 6933-40	5.4	11
1	Monoclonal antibody against a tumor-associated sialoglycoprotein of superficial papillary bladder tumors and cervical condylomas. <i>International Journal of Cancer</i> , 1990 , 46, 990-7	7.5	30